



iTeos Therapeutics Enters Into Therapeutic Antibody Discovery Partnership with Adimab

January 17, 2016

Gosselies, Belgium – January 17, 2016 – iTeos Therapeutics SA, a biotechnology company with a track record of delivering therapeutics targeting the immune tumor micro-environment, today announced a new partnership for the discovery, development and commercialization of multiple, antibody-based therapeutic programs with Adimab, LLC. Under the terms of the agreement, Adimab will utilize its antibody discovery and optimization platform to identify fully human therapeutic antibodies against targets selected by iTeos Therapeutics. All product development, including manufacturing and clinical trials, will be coordinated by iTeos Therapeutics.

“We are very pleased to enter into this partnership with an emerging leader in the oncology field. iTeos has a strong management team and has demonstrated the capability to quickly develop valuable therapeutic programs,” said Tillman Gerngross, Chief Executive Officer of Adimab. “We are looking forward to applying the Adimab platform to discovering and engineering antibodies for iTeos.”

“Adimab is clearly an excellent strategic partner for iTeos Therapeutics. The speed and the quality of Adimab’s platform has consistently generated candidate drugs that are superior to the output from competing technologies,” said Christophe Quéva, Chief Scientific Officer of iTeos. “We are convinced that the Adimab platform will rapidly deliver to iTeos antibody drug candidates which will be clinically evaluated as monotherapy and in combination with leading immuno-oncology drugs to develop iTeos’ pipeline and partnering potentials for the benefit of patients with cancer.”

Over the past six years, Adimab has established partnerships with multiple leading pharmaceutical companies, including Merck, Roche, Novartis, Lilly, Genentech, Biogen, Novo Nordisk, Gilead, Kyowa Hakko Kirin, and GSK. Adimab’s partnerships range from single target funded discovery projects, to larger multi-target funded discovery collaborations, as well as full transfer and enablement of the Adimab Platform to pharmaceutical companies. These collaborations focus on IgG discovery, optimization, humanization and/or bispecifics for therapeutic products.

About iTeos Therapeutics SA

Based in Gosselies, Belgium, iTeos, a spin-off of Ludwig Cancer Research (LICR) and de Duve Institute (UCL), has built a discovery platform to identify therapeutics targeting the immune tumor micro-environment to optimize cancer immunotherapy and is now positioned to help deliver the next generation of cancer immunotherapies. iTeos combines expertise in tumor immunology with drug discovery of small molecules and biologics. The company entered into a strategic collaboration with Pfizer in December 2014. iTeos is developing partnerships with top-tier academic and industrial partners to develop new programs. iTeos is supported by the Walloon Region of Belgium and the FEDER (European Fund for Economic and Regional Development).